HUP9902889A2 - 3-Fenil-4-(4-metilszulfonil)-fenil-2-(5H)-furanon alkalmazása gyulladáscsökkentő gyógyszerkészítmény előállítására, és az ilyen készítmények - Google Patents
3-Fenil-4-(4-metilszulfonil)-fenil-2-(5H)-furanon alkalmazása gyulladáscsökkentő gyógyszerkészítmény előállítására, és az ilyen készítményekInfo
- Publication number
- HUP9902889A2 HUP9902889A2 HU9902889A HUP9902889A HUP9902889A2 HU P9902889 A2 HUP9902889 A2 HU P9902889A2 HU 9902889 A HU9902889 A HU 9902889A HU P9902889 A HUP9902889 A HU P9902889A HU P9902889 A2 HUP9902889 A2 HU P9902889A2
- Authority
- HU
- Hungary
- Prior art keywords
- phenyl
- cyclooxygenase
- compound
- medicaments
- furanone
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 2
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 3
- 238000011287 therapeutic dose Methods 0.000 abstract 2
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 abstract 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 1
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgya gyógyászati készítmény ciklooxigenáz-2 általmediált betegségek kezelésére, amely naponta egyszeri orálisadagolásra alkalmas, és ciklooxigenáz-2 inhibitor vegyületettartalmaz, amelyre jellemző, hogy (a) erős ciklooxigenáz-2 inhibitorhatást mutat, amely a vegyület egyszeri terápiás dózisának két vagyhárom őrlőfog eltávolításával járó műtét utáni fájdalmat csillapítóképességével mérhető, ami statisztikusan egyenlő vagy nagyobb, mint a400 mg ibuprofen egyszeri dózisával elérhető fájdalomcsillapító hatás;(b) felezési ideje legalább 15 óra; és (c) nagyfokú specificitássalgátolja a ciklooxigenáz-2-t a ciklooxigenáz-1-gyel szemben, amelyazzal mérhető, hogy a vegyület terápiás dózisa statisztikusan nemgátolja szérumban a tromboxán B2 képződését. Ilyen vegyület például a3-fenil-[4-(4-metilszulfonil)-fenil]-2-(5H)-furanon. A találmányszerinti készítmény 5-125 mg fenti vegyületet tartalmaz. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1787896P | 1996-05-17 | 1996-05-17 | |
| GBGB9612063.9A GB9612063D0 (en) | 1996-06-10 | 1996-06-10 | Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases |
| PCT/US1997/008041 WO1997044028A1 (en) | 1996-05-17 | 1997-05-13 | Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9902889A2 true HUP9902889A2 (hu) | 2002-01-28 |
| HUP9902889A3 HUP9902889A3 (en) | 2002-04-29 |
Family
ID=26309472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9902889A HUP9902889A3 (en) | 1996-05-17 | 1997-05-13 | The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6063811A (hu) |
| EP (1) | EP0910368A1 (hu) |
| JP (1) | JPH11512754A (hu) |
| KR (1) | KR100373622B1 (hu) |
| CN (1) | CN1140267C (hu) |
| AR (1) | AR012014A1 (hu) |
| AU (1) | AU3004997A (hu) |
| BG (1) | BG103000A (hu) |
| BR (1) | BR9709097A (hu) |
| CA (1) | CA2254061C (hu) |
| CO (1) | CO5050370A1 (hu) |
| CZ (1) | CZ291463B6 (hu) |
| DZ (1) | DZ2200A1 (hu) |
| EA (1) | EA001596B1 (hu) |
| EE (1) | EE03746B1 (hu) |
| HK (1) | HK1021623A1 (hu) |
| HR (1) | HRP970262A2 (hu) |
| HU (1) | HUP9902889A3 (hu) |
| ID (1) | ID16921A (hu) |
| IL (1) | IL126899A (hu) |
| IS (1) | IS4891A (hu) |
| MY (1) | MY116201A (hu) |
| NO (1) | NO985342D0 (hu) |
| NZ (1) | NZ332670A (hu) |
| PE (1) | PE66998A1 (hu) |
| PL (1) | PL188649B1 (hu) |
| SK (1) | SK284330B6 (hu) |
| TR (1) | TR199802345T2 (hu) |
| WO (1) | WO1997044028A1 (hu) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
| EP1061908A4 (en) * | 1998-03-13 | 2007-01-24 | Merck & Co Inc | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY MIXING SYNDROME AND ASSOCIATED CONDITIONS |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| CO5190664A1 (es) | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
| GB9920558D0 (en) * | 1999-08-31 | 1999-11-03 | Bradford Particle Design Ltd | Methods for particle formation and their products |
| JP2003518061A (ja) * | 1999-12-22 | 2003-06-03 | ファルマシア コーポレイション | シクロオキシゲナーゼ−２阻害剤の持続放出製剤 |
| DK1296665T3 (da) | 2000-06-13 | 2011-07-18 | Wyeth Llc | Analgetiske og antiinflammatoriske sammensætninger indeholdende celecoxib og ibuprofen |
| AU2001285011A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia Corporation | Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| WO2002017896A2 (en) * | 2000-08-29 | 2002-03-07 | Peter Van Patten | Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid |
| AR030630A1 (es) * | 2000-09-11 | 2003-08-27 | Novartis Ag | Composiciones farmaceuticas |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| EP1423114A4 (en) * | 2001-05-04 | 2006-05-17 | Merck & Co Inc | METHOD AND COMPOSITIONS FOR TREATING MIGRAINE |
| PE20030323A1 (es) * | 2001-08-31 | 2003-05-12 | Novartis Ag | Composicion farmaceutica |
| WO2003026697A2 (en) * | 2001-09-26 | 2003-04-03 | Pharmacia Corporation | Organoleptically acceptable intraorally disintegrating compositions |
| OA12666A (en) * | 2001-10-10 | 2006-06-19 | Pharmacia Corp Corporate Paten | Intraorally disintegrating valdecoxib compositionsprepared by spray drying process. |
| AU2003227039B2 (en) * | 2002-03-07 | 2007-04-19 | Novartis Ag | Pharmaceutical compositions |
| ES2214129B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 3-fenilfuran-2-onas. |
| ES2213485B1 (es) | 2003-02-13 | 2005-12-16 | Almirall Prodesfarma, S.A. | Derivados de la 2-fenilpiran-4-ona. |
| PL1745791T3 (pl) | 2003-05-07 | 2013-11-29 | Osteologix As | Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu |
| TR200301552A1 (tr) * | 2003-09-18 | 2005-10-21 | Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Rofekoksib' in yeni oral farmakolojik formülasyonları. |
| CA2676413A1 (en) * | 2007-01-19 | 2008-07-31 | Mallinckrodt Inc. | Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| KR20210124188A (ko) | 2018-11-21 | 2021-10-14 | 트루모 파마슈티칼스, 인크. | 정제된 형태의 로페콕시브, 제조 및 사용 방법 |
| US20200323813A1 (en) * | 2019-04-09 | 2020-10-15 | Tremeau Pharmaceuticals, Inc. | Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal anti-inflammatory drugs |
| US10945992B1 (en) | 2019-11-13 | 2021-03-16 | Tremeau Pharmaceuticals, Inc. | Dosage forms of rofecoxib and related methods |
| US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| CA2180651A1 (en) * | 1994-01-10 | 1995-07-13 | Yves Ducharme | Phenyl heterocycles as cox-2 inhibitors |
-
1997
- 1997-05-13 CA CA002254061A patent/CA2254061C/en not_active Expired - Fee Related
- 1997-05-13 JP JP9542486A patent/JPH11512754A/ja active Pending
- 1997-05-13 EP EP97924688A patent/EP0910368A1/en not_active Withdrawn
- 1997-05-13 WO PCT/US1997/008041 patent/WO1997044028A1/en not_active Application Discontinuation
- 1997-05-13 KR KR10-1998-0709239A patent/KR100373622B1/ko not_active IP Right Cessation
- 1997-05-13 CZ CZ19983738A patent/CZ291463B6/cs not_active IP Right Cessation
- 1997-05-13 BR BR9709097A patent/BR9709097A/pt not_active IP Right Cessation
- 1997-05-13 US US09/180,647 patent/US6063811A/en not_active Expired - Lifetime
- 1997-05-13 NZ NZ332670A patent/NZ332670A/xx unknown
- 1997-05-13 SK SK1567-98A patent/SK284330B6/sk unknown
- 1997-05-13 CN CNB971963150A patent/CN1140267C/zh not_active Expired - Fee Related
- 1997-05-13 AU AU30049/97A patent/AU3004997A/en not_active Abandoned
- 1997-05-13 HU HU9902889A patent/HUP9902889A3/hu unknown
- 1997-05-13 IL IL12689997A patent/IL126899A/en not_active IP Right Cessation
- 1997-05-13 EA EA199801017A patent/EA001596B1/ru not_active IP Right Cessation
- 1997-05-13 EE EE9800393A patent/EE03746B1/xx not_active IP Right Cessation
- 1997-05-13 TR TR1998/02345T patent/TR199802345T2/xx unknown
- 1997-05-14 AR ARP970102021A patent/AR012014A1/es unknown
- 1997-05-14 DZ DZ970087A patent/DZ2200A1/fr active
- 1997-05-15 PE PE1997000379A patent/PE66998A1/es not_active Application Discontinuation
- 1997-05-16 HR HR9612063.9A patent/HRP970262A2/xx not_active Application Discontinuation
- 1997-05-16 ID IDP971640A patent/ID16921A/id unknown
- 1997-05-16 MY MYPI97002138A patent/MY116201A/en unknown
- 1997-05-16 CO CO97026568A patent/CO5050370A1/es unknown
-
1998
- 1998-11-10 IS IS4891A patent/IS4891A/is unknown
- 1998-11-16 NO NO985342A patent/NO985342D0/no not_active Application Discontinuation
- 1998-12-08 BG BG103000A patent/BG103000A/xx unknown
-
1999
- 1999-01-11 PL PL97329940A patent/PL188649B1/pl not_active IP Right Cessation
-
2000
- 2000-02-02 HK HK00100645A patent/HK1021623A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9902889A2 (hu) | 3-Fenil-4-(4-metilszulfonil)-fenil-2-(5H)-furanon alkalmazása gyulladáscsökkentő gyógyszerkészítmény előállítására, és az ilyen készítmények | |
| Ngan et al. | The effect of ibuprofen on the level of discomfort inpatients undergoing orthodontic treatment | |
| Allen | Statistical study of the primary causes of extractions | |
| HUP9901779A2 (hu) | Módosított hatóanyag-leadású, többszörös adagolású gyógyászati készítmény, valamint eljárás előállítására | |
| HUP9904024A2 (hu) | Protonpumpa inhibitort és antacid szert vagy alginátot tartalmazó orális gyógyszeradagolási formák | |
| TR200002207T1 (tr) | Slekoksib bileşikleri. | |
| NO20004311L (no) | Farmasøytisk sammensetning av topiramat | |
| BG105005A (en) | Pyrazoline derivatives, their preparation and application as medicaments | |
| NO20053105L (no) | Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag. | |
| CA2241904A1 (en) | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | |
| AR019853A1 (es) | Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci | |
| HUP0003757A2 (hu) | Levosimendant tartalmazó orális gyógyászati készítmények | |
| ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| HUP0202671A2 (hu) | Ketotifen optikailag aktív izomerei és aktív metabolitjai | |
| Pellicer-Chover et al. | Comparative split-mouth study of the anesthetic efficacy of 4% articaine versus 0.5% bupivacaine in impacted mandibular third molar extraction | |
| AU4024797A (en) | Use of arachidonic acid and/or docosahexanoic acid for the manufacture of a medicament for the treatment of dyspraxia | |
| RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
| HUP9900978A2 (hu) | Dioszgenint tartalmazó készítmény | |
| WO1995004520A1 (en) | Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection | |
| Smith et al. | Inhibition of tissue prostaglandin synthesis during third molar surgery use of preoperative fenbufen | |
| Karabetsos et al. | Ketoprofen versus paracetamol in the treatment of acute migraine | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| HUP0301408A2 (hu) | Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására | |
| US4879106A (en) | Methods for treating gingivitis and paradental pyorrhea | |
| Russek et al. | Comparative responses to various nitrates in the treatment of angina pectoris |